CymaBay Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CBAY and buy or sell other stocks, ETFs, and their options commission-free!About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001.
CEOAndrew D. Dickinson
CEOAndrew D. Dickinson
Employees—
Employees—
HeadquartersFoster City, California
HeadquartersFoster City, California
Founded1988
Founded1988
Employees—
Employees—
CBAY Key Statistics
Market cap3.73B
Market cap3.73B
Price-Earnings ratio-32.75
Price-Earnings ratio-32.75
Dividend yield—
Dividend yield—
Average volume1.85M
Average volume1.85M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$32.50
52 Week high$32.50
52 Week low$7.26
52 Week low$7.26
Stock Snapshot
As of today, CymaBay Therapeutics(CBAY) shares are valued at $32.48. The company's market cap stands at 3.73B, with a P/E ratio of -32.75.
On 2025-12-17, CymaBay Therapeutics(CBAY) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 1.85M.
The stock's 52-week range extends from a low of $7.26 to a high of $32.50.
The stock's 52-week range extends from a low of $7.26 to a high of $32.50.
People also own
Based on the portfolios of people who own CBAY. This list is generated using Robinhood data, and it’s not a recommendation.